ABSTRACT
<p><b>OBJECTIVE</b>To evaluate the clinical effect and safety of dapoxetine in the treatment of premature ejaculation (PE).</p><p><b>METHODS</b>We randomly assigned 116 PE patients to receive dapoxetine on demand at 30 mg qd (dapoxetine group, n = 60, aged 23-49 years) or oral tamsulosin at 20 mg qd (control group, n = 56, aged 24-46 years). After 4 weeks of medication, we compared the clinical global impression of change (CGIC) , PE profile (PEP) scores, intravaginal ejaculation latency time (IELT) , and adverse reactions between the two groups of patients.</p><p><b>RESULTS</b>Compared with the baseline, the IELT was remarkably prolonged after treatment both in the dapoxetine group ([0.86 ± 0.17] vs [4.32 ± 2.23] min, P < 0.05) and the control ([0.88 ± 0.15] vs [4.17 ± 2.26] min, P < 0.05), with no statistically significant difference between the two groups (P > 0. 05). The post-treatment rate of CGIC in the dapoxetine group had no statistically significant difference from that in the control (85.00% vs 82.14%, P > 0.05). In comparison with pre-treatment, the patients of both the dapoxetine and control groups showed dramatically improved scores after medication in perceived control over ejaculation (0.85 ± 0.23 vs 2.13 ± 0.97 and 0.88 ± 0.21 vs 2.06 ± 0.34, both P < 0.05), ejaculation-related personal distress (1.15 ± 0.64 vs 2.89 ± 0.26 and 1.19 ± 0.53 vs 2.82 ± 0.69, both P < 0.05), satisfaction with sexual intercourse (0.81 ± 0.33 vs 2.58 ± 0.37 and 0.79 ± 0.28 vs 2.45 ± 0.32, both P < 0.05), and ejaculation-related interpersonal difficulty (2.05 ± 0.61 vs 3.24 ± 0.35 and 2.03 ± 0.65 vs 3.18 ± 0.76, both P < 0.05), with no significant differences between the two groups (P > 0.05). The incidence of adverse reactions was significantly lower in the dapoxetine than in the control group (3.33% vs 30.36%, P < 0.05).</p><p><b>CONCLUSION</b>Dapoxetine is effective for the treatment of PE, with its advantages of prolonging the intravaginal ejaculation latency time, improving the quality of sexual life, and low incidence of adverse reactions.</p>
Subject(s)
Adult , Humans , Male , Middle Aged , Young Adult , Benzylamines , Therapeutic Uses , Coitus , Double-Blind Method , Ejaculation , Naphthalenes , Therapeutic Uses , Patient Satisfaction , Premature Ejaculation , Drug Therapy , Selective Serotonin Reuptake Inhibitors , Therapeutic Uses , Sexual Behavior , Sulfonamides , Therapeutic Uses , Treatment OutcomeABSTRACT
Objective To elucidate the effects of erythromycin derivative,9(S)-hydroxyerythromycin, on the expression of NF-?B in active T lymphocytes,and evaluate the potential role in the treatment of rheuma- toid arthritis(RA).Methods Jurkat T cells were exposed to 100 pmol/L tumor necrosis factor(TNF)-?with or without pretreatment with 3,10,30 or I00?g/ml of erythromycin or 9(S)-hydrnxyerythromycin 1 h at 37℃. The expression of NF-?B was measured by reverse transcription-polymerase chain reaction(RT-PCR)and Western blot.Results Erythromycin and 9(S)-hydroxyerythromycin decreased the expression of NF-?B mRNA and protein in a dose-related fashion.The treatments with erythromycin(100?g/ml)and 9(S)-hydrox- yerythromycin(100?g/ml)resulted in about 36%,45% reduction of NF-?B mRNA(P